Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome
- 30 November 2003
- journal article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 78 (11), 1340-1346
- https://doi.org/10.4065/78.11.1340
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Expanding use of rituximab in immunopathic disordersBlood, 2003
- Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adultsBritish Journal of Haematology, 2002
- Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapsesAnnals of Hematology, 2002
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002
- Autoimmune hemolytic anemiaAmerican Journal of Hematology, 2002
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable ToxicityJournal of Clinical Oncology, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997